Arcus Biosciences, Inc. Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
Arcus Biosciences, Inc. (RCUS) had Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount of $0 as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount · last filed 2021-08-05
- 2021-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-03-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-12-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-09-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 |
| 2020-12-31 | $0.00 10-Q · filed 2021-08-05 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-05 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-02 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-05 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |